JNJ vs PFE
Johnson & Johnson vs Pfizer Inc. · Updated Mar 28, 2026
JNJ — 14 winsPFE — 9 wins
Price Performance
JNJ +46.88%PFE +7.26%
Performance
| JNJ | PFE | |
|---|---|---|
| 1 Month | -1.52% | -0.17% |
| 3 Months | +15.40% | +8.09% |
| 6 Months | +34.91% | +14.64% |
| YTD | +15.86% | +8.65% |
| 1 Year | +48.27% | +7.32% |
| 3 Year | +45.35% | -47.28% |
| 5 Year | +67.20% | -26.60% |
Yearly Returns
| YTD | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| JNJ | +16.0% | +43.7% | -9.6% | -12.0% | +3.0% | +9.3% | +7.8% | +14.2% | -7.3% | +20.6% | +14.7% | -1.7% |
| PFE | +7.4% | -6.4% | -10.8% | -43.8% | -9.4% | +60.4% | -0.8% | -9.4% | +19.8% | +9.8% | +1.6% | +3.0% |
Valuation
| JNJ | PFE | |
|---|---|---|
| P/E Ratio | 21.72 | 19.89 |
| Forward P/E | 20.58 | 9.36 |
| PEG Ratio | 2.47 | — |
| P/S Ratio | 6.02 | 2.45 |
| P/B Ratio | 6.96 | 1.77 |
| EV/EBITDA | 14.78 | 13.09 |
Financials
| JNJ | PFE | |
|---|---|---|
| EPS (TTM) | $11.04 | $1.36 |
| Gross Margin | +67.56% | +69.97% |
| Operating Margin | +20.22% | -9.35% |
| Net Margin | +20.83% | -9.34% |
| ROE | +32.87% | +9.00% |
| ROA | +13.46% | +3.75% |
| Debt/Equity | 0.51 | 0.78 |
Growth
| JNJ | PFE | |
|---|---|---|
| Revenue Growth YoY | +9.08% | -1.16% |
| Revenue Growth QoQ | +2.38% | +5.42% |
| EPS Growth YoY | +48.23% | -514.29% |
| EPS Growth QoQ | -1.42% | -146.77% |
Technical
| JNJ | PFE | |
|---|---|---|
| RSI (14) | 49.94 | 47.28 |
| % From 20-Day SMA | -0.41% | +0.16% |
| % From 50-Day SMA | +1.21% | +0.93% |
| % From 200-Day SMA | +21.93% | +6.58% |
| % From 52-Week High | -4.74% | -3.17% |
| % From 52-Week Low | +69.46% | +29.36% |
Analyst Ratings
JNJ
Buy(37 analysts)
Strong SellHoldStrong Buy
Price Target
$228.73
-2.73% upside
PFE
Hold(12 analysts)
Strong SellHoldStrong Buy
Price Target
$27.50
+2.36% upside
Overview
| JNJ | PFE | |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Drug Manufacturers - General |
| Exchange | NYSE | NYSE |
| Market Cap | $567.22B | $153.44B |
| Shares Outstanding | 2.41B | 5.69B |
| Avg Volume (10D) | 7.97M | 41.21M |
| Dividend Yield | 2.21% | 6.37% |
Frequently Asked Questions
Is JNJ or PFE a better buy right now?
Based on 23 comparable metrics, JNJ leads in 14 categories while PFE leads in 9. JNJ has a consensus analyst rating with 37 analysts covering the stock. Neither stock should be purchased based on a single comparison — consider your investment goals and risk tolerance.
Which stock has better performance, JNJ or PFE?
Over the past year, JNJ returned +48.27% compared to PFE's +7.32%. In the short term (1 month), JNJ returned -1.52% vs PFE's -0.17%.
Is JNJ or PFE more expensive?
JNJ trades at a P/E of 21.72 compared to PFE's 19.89. On a price-to-sales basis, JNJ trades at 6.02x vs PFE's 2.45x. Forward P/E: JNJ at 20.58 vs PFE at 9.36.
Which stock has higher growth, JNJ or PFE?
JNJ's revenue grew +9.08% year-over-year compared to PFE's -1.16%. EPS growth: JNJ at +48.23% vs PFE at -514.29%.
Do JNJ and PFE pay dividends?
JNJ pays a dividend with a yield of 2.21%. PFE pays a dividend with a yield of 6.37%.
Which stock do analysts prefer, JNJ or PFE?
JNJ has 37 analysts with a target price of $228.73 (-2.73% upside). PFE has 12 analysts with a target of $27.50 (+2.36% upside).
Data updated daily. All comparisons based on latest available market data. Not investment advice.